Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases
Antimicrobial Agents and Chemotherapy · 03.04.2024 · 68 (4)
DOI: 10.1128/aac.01548-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.04.2024. Verfasst von Christophe Le Terrier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerla…. Hauptthemen laut MEDLINE: Aztreonam, Cefiderocol, Borinic Acids, Boronic Acids. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Fribourg.
Abstract (Originalsprache)
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and to cefiderocol. A large series of E. coli recombinant strains producing broad-spectrum β-lactamases was evaluated. While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
ORCID-Profile: Christophe Le Terrier, Patrice Nordmann, Laurent Poirel
Förderung
- University of Fribourg
Zitieren
APA
Le Terrier, C., Nordmann, P., Buchs, C., & Poirel, L. (2024). Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy, 68(4). https://doi.org/10.1128/aac.01548-23
Vancouver
Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy. 2024;68(4). doi:10.1128/aac.01548-23
BibTeX
@article{LeTerrier2024,
author = {Le Terrier, Christophe and Nordmann, Patrice and Buchs, Chloé and Poirel, Laurent},
title = {Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {4},
doi = {10.1128/aac.01548-23}
}
EUVIMED